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Abstract
Background: To assess the neurological involvement and outcome, including school and professional
performances, of adults and children with cryopyrin-associated periodic syndrome (CAPS).
Methods: In this observational study, patients with genetically proven CAPS and followed in the national referral
centre for autoinflammatory diseases at Bicêtre hospital were assessed. Neurological manifestations, CSF data and
MRI results at diagnosis and during follow-up were analyzed.
Results: Twenty-four patients (15 adults and 9 children at diagnosis) with CAPS were included. The median age at
disease onset was 0 year (birth) [range 0–14], the median age at diagnosis was 20 years [range 0–53] and the mean
duration of follow-up was 10.4 ± 2 years. Neurological involvement at diagnosis, mostly headaches and hearing loss,
was noted in 17 patients (71%). Two patients of the same family had abnormal brain MRI. A439V mutation is
frequently associated with a non-neurological phenotype while R260W mutation tends to be associated with
neurological involvement. Eleven adult patients (61%) and 3 children (50%) underwent school difficulties.
Conclusion: Neurological involvement is frequent in patients with CAPS and the majority of patients presented
difficulties in school performances with consequences in the professional outcome during adulthood. Further
studies in larger cohorts of children with CAPS focusing in intellectual efficiency and school performances are
necessary.
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Background
Cryopyrin-associated periodic syndrome (CAPS) is a rare
hereditary periodic fever syndrome with an estimated
prevalence in France equal to 1/360 000 [1]. CAPS are
caused by dominantly inherited, or de novo, gain of
function mutations within the NLRP3 gene [1, 2]. NRLP3
encodes cryopyrin, which controls the activation of
caspase-1 which in turn catalyses the cleavage of
prointerleukin-1β (IL-1β) into the potent proinflammatory
cytokine IL-1β [3]. Mutations of NRLP3 are associated
with overactivation of the inflammasome and thus overex-
presion of IL-1β. Because of this overproduction of IL-1, a
specific treatment of CAPS using anti- IL-1 β monoclonal
antibodies such as canakinumab which is a human anti-
interleukin-1 β monoclonal antibody are used [4].
The syndrome encompasses a continuum of three
diseases, from the mildest familial cold autoinflamma-
tory syndrome (FCAS) to the most severe Neonatal
Onset Multisystem Inflammatory Disease (NOMID)
also known as Chronic Infantile Neurologic Cutaneous
Articular (CINCA) syndrome. The Muckle-Wells
syndrome (MWS) has an intermediate phenotype [5, 6].
The clinical manifestations of CAPS such as urticaria-like
skin rash, eyes redness, myalgia and sensory deafness, are
not specific, if considered separately, and that often leads
to a diagnostic delay which compromises the quality of life
and exposes the patients to neurosensory complications
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and renal failure by secondary amyloidosis [5, 7, 8].
Central nervous system manifestations in this syndrome
can also occur with various abnormalities on brain MRI
[6]. Patients with leptomeningeal or dural enhancement
had significantly lower IQ levels than did patients without
enhancement. These manifestations are not well known
especially by clinicians with a possible underestimation of
neurological involvement [9].
The aim of our study is to assess neurological involve-
ment and outcome, including school and professional
performances, especially under canakinumab treatment
of adults and children with CAPS.
Methods
Patients
We analyzed retrospectively data of patients with genetic-
ally proven CAPS, followed in the referral center for rare
autoinflammatory diseases from January 2002 to January
2015. We identified 24 patients and collected demo-
graphic data, age at onset, age at diagnosis and clinical
characteristics: fever, skin involvement, musculo-skeletal
and ocular manifestations. All patients were followed since
their childhood and underwent at least one clinical
examination by a neurologist or a pediatric neurologist.
Neurological manifestations were defined by any clinical
symptoms of neurological involvement: headaches,
meningeal syndrome, sensorineural deafness (confirmed
by audiograms), optic nerve involvement (based on fundu-
scopic examination), seizures, mental retardation (con-
firmed by psychometrics tests when available). Headaches
were characterized as migraines or not-migraines accord-
ing to the International Classification of Headache
Disorders, 2nd edition. CSF data were collected when
available (cells > 5/mm3, proteins >0,4 g/dl, CSF opening
pressure > 20 mm H2O). Brain MRI (T1, T2, T2 FLAIR,
before and after injection of gadolinium, T2* weighted
sequences, if available) at diagnostic and during follow-
up, were read by two trained pediatric neurologist
(NM and KD).
We reported the neurological outcome of these patients
based on neurological examination, MRI results and
audiometry tests during follow-up. We described their
school performances: patients were considered to have
learning difficulties if there were academic accommoda-
tions, grade repetition, early school leaving, or needing of
special education classes. We also described the profes-
sional categories of the adult patients with CAPS based on
the French National Institute of Statistics (INSEE) classifi-
cation (Guide des nomenclatures professions et categories
socio-professionnelles 2003).
We also analyzed the efficacy of canakinumab on
neurological signs. The treatment was considered to be
efficient if there was a complete resolution of headaches
or if the frequency of these headaches was less than once
a month. A partial response was defined if the headaches
occured more than once a month. Hearing loss evolu-
tion under treatment was evaluated by repeated audi-
ometry tests during follow-up: stable, improvement or
worsening.
Statistical analysis
Statistical analysis was carried out with SPSS version
19.0. Parametric or nonparametric tests (Kruskal-Wallis
and Mann–Whitney U tests) were used for continuous
measurements as appropriate given normality. Differences
were considered significant for p values <0.05.
Results
Twenty-four patients (15 adults and 9 children at diagnosis)
with CAPS were analyzed. The median age at disease onset
was 0 year (birth) [range 0–14], the median age at diagnosis
was 20 years [range 0–53] and the mean duration of
follow-up was 10,4 ± 2 years. Two patients had no family
history of CAPS.
Skin rash, musculo-skeletal involvement and fever
were the most prevalent features as described in Table 1
and neurological involvement at diagnosis was noted in
17 patients (71%). One patient had a mental retardation
confirmed by neuropsychological tests (WISC IV), one
patient had psychotic disorder. Fourteen (58%) patients
had learning difficulties needing academic accommoda-
tions (Table 1).
The A439V mutation was frequently associated with
no neurological signs and R260W tended to be associ-
ated with neurological symptoms (Table 2).
All but one patient underwent at least one brain MRI
before treatment. One brain MRI among 23 was abnor-
mal before IL-1β treatment showing white matter lesions
(Fig. 1a, b). The clinical examination of this 45-year-old
female who had a heterozygous R260W mutation re-
vealed no clinical neurological abnormalities. These MRI
lesions were characterized as multiple sclerosis-like le-
sions. Two lesions appeared on brain MRI after one year
of treatment (Fig. 1c, d). After that, MRI remained stable
as well as her clinical neurological examination and the
patient was already reported in the literature by our
group [10]. The MRI of one 25 year-old patient showed
T2 lesions after seven years of canakinumab treatment
and with no clinical consequences (Fig. 2). Lesions were
compatible with a vasculitis. These 2 patients are from
the same family and carry the same mutation R260W.
Five patients (21%) underwent a CSF analysis; the
opening pressure of the CSF was measured for 3 of
them: 2 patients had an aseptic meningitis and the CSF
opening pressure of one patient was elevated at 36 mm
H2O. These two patients had not migraine-headaches.
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The patients who had multiple sclerosis-like MRI
lesions underwent after 8 months of imaging, a CSF
analysis, which was normal.
Twenty-one patients (87%) are treated with canakinu-
mab (starting at a dose of 150 mg every 8 weeks for adults
and 2 mg/kg for children administrated as a subcutaneous
injection). Treatment was not started in two children
(9 and 4 years old) as their symptoms had very low
impact in their everyday life. One 42 year-old female
patient still refuses the treatment.
Fourteen (82%) of the treated patient described
improvement of their headaches: a complete resolution
of headaches in 12 patients (80%) and partial resolution
in 2 (13%) was observed. One patient had no improve-
ment of his migrainous headaches under treatment. The
elevated opening CSF pressure of one patient, normal-
ized two years after treatment onset.
Eight (80%) patients reported improvement (n = 3) or
stabilization (n = 5) of their hearing loss proven by audi-
ometry during follow up.
At follow-up, 6 patients were less than 18 years old,
among them 3 (50%) have learning difficulties needing
school accommodations, and 3 (50%) have no school
difficulties. The professional categories of adult patients
(n = 18) are described in (Fig. 3). Eleven adult patients
(61%) underwent school difficulties, at follow-up 3 have
no jobs, 3 are workers, 1 is a skilled worker and 4 are
employees. Among adults who had no school difficulties,
4 are post-graduate students, 1 is an employee and 2 are
skilled workers (Fig. 3).
Discussion
In this retrospective observational study, neurological
involvement concerns 71% of patients with CAPS,
mostly with headaches and neurosensorial hearing loss.
Canakinumab treatment confirms its efficacy in neuro-
logical symptoms in 76% of treated patients [4]. The
most important findings in our study is the impact of
CAPS on school performances: 50% of patients under
18 years old with CAPS have learning difficulties need-
ing school accommodations, and 61% of adult patients
had school difficulties with probable consequences in
their professional careers.
In the largest CAPS study based on Eurofever registry
(n = 136), neurological manifestations were observed in
40% and is mostly represented by headaches (70%),
papilledema (52%), meningitis (26%), hydrocephalus
(18%), mental retardation (16%), seizures (4%) [9]. Hearing
loss which is secondary to a cochlear inflammation repre-
sented 42% and was not included in the neurological
symptoms, which can explain the underestimation of
neurological involvement [9]. In our study, we confirmed
that headaches and hearing loss were the most prominent
neurological symptoms,
The mechanism of headaches in patients with CAPS is
not well known. In our study, 4 patients (27%) had mi-
grainous headaches and 2 patients with non-migrainous
headaches had an aseptic meningitis and one of them
had a high opening CSF pressure showing an intracra-
nial hypertension which can explain the headaches [11].
Only 21% of our patients underwent CSF analysis and
CSF opening pressure was measured only for 2 patients.





A439V (%) 1 (25) 3 (75)
R260W (%) 12 (60) 0 (0)
T348M (%) 3 (15) 1 (25)
Other mutations (%) 4 (20) 0 (0)
Table 1 Characteristics of the patients with CAPS
n = 24 %
Female sex 14 58
Familial history of CAPS 22 92
Genotype R260W 12 50
A439V 4 17
T348M 4 17
Other mutations 4 17
Age at onset (years) 0 [0–14]





Skin involvement 24 100
Urticarial rash 23 96




Neurological signs 17 71
Headaches 15 62




Hearing loss 10 59
Optic nerve atrophy 2 8
Mental retardation 1 0,04
Learning difficulties 14 58
Abnormal brain MRI (n = 23) 2 0,09
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Fig. 1 Brain MRI lesions of 52 year-old patient with CAPS before and after treatment. Axial FLAIR brain MRI images showing well limited
periventricular (a), corpus callosum (a) and juxtacortical lesions (b). Brain MRI images with Axial FLAIR sequences (c) and T1 after gadolinium
injection sequences (d), after one year of canakinumab treatment, of the same patient showing new FLAIR right paraventricular abnormalities
with Gadolinium enhancement
Fig. 2 MRI images of 26 year-old patient with CAPS during a relapse with severe headaches. (a): Axial Flair images showing T2 FLAIR hypersignal
right frontal juxta-cortical lesions with (b) hyposignal lesions on T2* weighted sequences suggesting hemosiderin deposits and (c) right anterior
cingular gyrus T2 FLAIR hypersignal with (d) gadolinium enhancement
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Unfortunately, CSF assays was not exhaustive and intra-
cranial hypertension and or chronic meningitis might be
under-estimated. A high level of pro-inflammatory
cytokines including IL-1β in patients with migraines had
been described [12]. This may be relevant to understand
the physiopathological mechanism of headaches in
CAPS and can explain canakinumab efficacy which was
complete for 2 of 4 patients with migrainous headaches.
Fifty nine percent of the patients with CAPS have a
hearing loss. The physiopathology is not well known, it
has been observed that some children with CINCA had
a cochlear inflammation demonstrated on MRI, after
IL-1 receptor antagonist treatment there was an im-
provement of cochlear enhancement [6]. In our study,
no cochlear inflammation has been described on MRI
but this imaging was not specifically performed for inner
ear disease, and cochlear abnormality on MRI may have
not been seen.
Before any anti- IL-1β treatment, one patient had
white matter lesions with demyelination as it may be
seen in multiple sclerosis without any neurological sign
(except for chronic headaches) unlike the only other
CAPS patient described in literature with demyelinating
disease who had a hemiparesia [13]. In MS, it has been
suggested that brain lesions may also be induced follow-
ing inflammatory synaptopathy and neurodegeneration
caused by IL-1β [14] and a similar mechanism may
explain brain lesions in patients with CAPS syndrome.
Recent studies suggested that IL-1 receptor antagonist
(IL-1Ra) could cross the blood–brain barrier and have a
neuroprotective effects in rodent model as well as in pa-
tients with ischemic stroke or subarachnoid hemorrhage
brain hemorrhage [15]. Under anti-IL-1β, in one patient
with white matter lesions before the start of treatment, 2
new lesions appeared after one year of treatment. There-
after, all brain MRI of this patient remained stable
suggesting that the lesion may eventually be associated
with the disease and treatment may have an effect on
long term.
Although we could not perform statistical test du to
small numbers of included patients, we have observed
that A439V mutation is frequently associated with a
non-neurological phenotype as previously published [9].
Interestingly, we also noticed that R260W mutation,
tend to be associated with neurological involvement.
Moreover 2 members of the same family with this
mutation had brain MRI lesions suggesting that brain
lesions in these patients may be linked to the disease.
Larger studies are needed to detect any specific pattern
of these lesions.
Our study described the neurological outcome under
anti- IL-1β treatment with a mean duration of follow-up
of 10,4 years. Canakinumab had shown its sustained effi-
cacy on neurological symptoms: 82% improved their
headaches under treatment, and 80% improved or stabi-
lized their hearing loss. In our study the median age at
onset is birth and the median age at diagnosis is 20 years.
There is an important delay of diagnosis and therefore a
delay for treatment, already noted in previous studies
[9]. This highlights the importance of recognizing the
clinical features of this rare syndrome for neonatologists,
pediatrician and pediatric neurologist in order to initiate
the specific treatment and reverse systemic symptoms as
well as neurological symptoms and prevent progression
of them, especially headaches and hearing loss.
Our study focused on school performances and profes-
sional career during follow-up. Although there is only
one objective mental retardation, school difficulties are
Fig. 3 Professional categories of adults with CAPS (n = 18)
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frequent in children with CAPS. The cognitive difficul-
ties may be under-estimated: only 4 patients underwent
psychometric tests. The impact of CAPS in school and
professional performances is multifactorial: chronic
pains, school absences, sick leaves are also implicated. A
recent study showed on 7 patients in a prospective
monocentric study that canakinumab had not only a
sustained effect on quality of life, but also allowed dra-
matic changes in social and work lives [16]. The benefit
of canakinumab treatment in allowing a professional life
was one of their most important observations; no
patients were out of work during the follow-up (4.8 ±
0.8 years). The gain in vitality scores permitted them to
enjoy a social life after work and physical activity, which
were impossible without treatment. Psychometric tests,
neuropsychological evaluation, neuropediatric follow-up
is not systematic for children with CAPS, although the
learning difficulties are frequent in these patients as
shown in our study.
Conclusion
We provided a detailed description of the neurological
involvement, which is frequent in adults and children
with CAPS. Canakinumab seems to have changed the
general outcome of these patients as well as the neuro-
logical outcome. Further studies in larger cohorts of
children with CAPS focusing in intellectual efficiency
and school performances are necessary. Because of the
frequency of school difficulties shown in our study in
children with CAPS, the role of the pediatric neurologist
in the muldisciplinary follow-up of these patients is very
important and regular neuropsychological evaluations
and neurological following are advisable for children
with CAPS.
Abbreviations
CAPS: Cryopyrin-associated periodic syndrome; CINCA: Chronic Infantile
Neurologic Cutaneous Articular syndrome; CSF: Cerebro-spinal fluid;
MRI: Magnetic resonance imaging; MWS: Muckle-Wells syndrome;




No funding was obtained for this research.
Availability of data and materials
The datasets during and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
NM acquisition of data, analysis and interpretation of data, drafting the
article. HM and IM acquisition of data, revising the article critically. IKP and
KD substantial contributions to conception and design, acquisition of data,
analysis and interpretation of data, drafting the article and revising it
critically. All authors read and approved the final manuscript.
Competing interests
All authors have no conflicts of interest relevant to this article to disclose.
Consent for publication
Patients have given their consent to electronic storage and treatment of
their medical data.
Ethics Approval and Consent to Participate
According to our national regulations, no IRB approval was necessary.
Financial disclosures
NM, HM, IM have no financial disclosures. IKP has received consulting fees from
Novartis, Abbvie, Pfizer and Sobi. KD has received consulting fees from Novartis.
Author details
1Department of Pediatrics, Meaux General Hospital, 77104 Meaux Cedex,
France. 2Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris
Sud, Department of Pediatrics, Pediatric Rheumatology, National Referral
Centre of Auto-inflammatory Diseases, CEREMAI, CHU Bicêtre, University of
Paris Sud, Le Kremlin Bicêtre, France. 3Assistance Publique-Hôpitaux de Paris,
Hôpitaux Universitaires Paris Sud, Pediatric Neurology Department and
National Referral Center for Neuroinflammatory Diseases in Children and
Inserm UMR 1184, Center for immunology of viral infections and
autoimmune diseases, CEA, IDMIT, University Paris Sud, 63, rue Gabriel Péri,
94276 Le Kremlin-Bicêtre Cedex, France.
Received: 19 September 2016 Accepted: 7 February 2017
References
1. Cuisset L, Jeru I, Dumont B, Fabre A, Cochet E, Le Bozec J, Delpech M,
Amselem S, Touitou I. French Csg: Mutations in the autoinflammatory
cryopyrin-associated periodic syndrome gene: epidemiological study and
lessons from eight years of genetic analysis in France. Ann Rheum Dis.
2011;70(3):495–9.
2. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation
of a new gene encoding a putative pyrin-like protein causes familial cold
autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet.
2001;29(3):301–5.
3. Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory
syndromes. Annu Rev Med. 2014;65:223–44.
4. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E,
Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN, et al. Use of
canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med.
2009;360(23):2416–25.
5. Muckle TJ. Wellsm: Urticaria, deafness, and amyloidosis: a new heredo-
familial syndrome. Q J Med. 1962;31:235–48.
6. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim
HJ, Brewer C, Zalewski C, Wiggs E, et al. Neonatal-onset multisystem
inflammatory disease responsive to interleukin-1beta inhibition.
N Engl J Med. 2006;355(6):581–92.
7. Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory
syndrome: phenotype and genotype of an autosomal dominant periodic
fever. J Allergy Clin Immunol. 2001;108(4):615–20.
8. Kone-Paut I. Cryopyrine-associated periodic syndrome: CAPS seen from
adulthood. Rev Med Interne. 2015;36(4):277–82.
9. Levy R, Gerard L, Kuemmerle-Deschner J, Lachmann HJ, Kone-Paut I,
Cantarini L, Woo P, Naselli A, Bader-Meunier B, Insalaco A, et al. Phenotypic
and genotypic characteristics of cryopyrin-associated periodic syndrome:
a series of 136 patients from the Eurofever Registry. Ann Rheum Dis.
2015;74(11):2043–9.
10. Compeyrot-Lacassagne S, Tran TA, Guillaume-Czitrom S, Marie I, Kone-Paut I.
Brain multiple sclerosis-like lesions in a patient with Muckle-Wells syndrome.
Rheumatology (Oxford). 2009;48(12):1618–9.
11. Kitley JL, Lachmann HJ, Pinto A, Ginsberg L. Neurologic manifestations of
the cryopyrin-associated periodic syndrome. Neurology. 2010;74(16):1267–70.
12. Perini F, D'Andrea G, Galloni E, Pignatelli F, Billo G, Alba S, Bussone G, Toso
V. Plasma cytokine levels in migraineurs and controls. Headache.
2005;45(7):926–31.
13. Lequerre T, Vittecoq O, Saugier-Veber P, Goldenberg A, Patoz P, Frebourg T,
Le Loet X. A cryopyrin-associated periodic syndrome with joint destruction.
Rheumatology (Oxford). 2007;46(4):709–14.
14. Rossi S, Motta C, Studer V, Macchiarulo G, Volpe E, Barbieri F, Ruocco G,
Buttari F, Finardi A, Mancino R, et al. Interleukin-1beta causes excitotoxic
Mamoudjy et al. Orphanet Journal of Rare Diseases  (2017) 12:33 Page 6 of 7
neurodegeneration and multiple sclerosis disease progression by activating
the apoptotic protein p53. Mol Neurodegener. 2014;9:56.
15. Singh N, Hopkins SJ, Hulme S, Galea JP, Hoadley M, Vail A, Hutchinson PJ,
Grainger S, Rothwell NJ, King AT, et al. The effect of intravenous interleukin-
1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after
subarachnoid haemorrhage: a phase II randomised controlled trial.
J Neuroinflammation. 2014;11:1.
16. Marsaud C, Marie I, Kone-Paut I. Longterm followup of quality of life in
patients with cryopyrin-associated periodic syndrome treated with
canakinumab, an anti-interleukin 1beta monoclonal antibody. J Rheumatol.
2014;41(8):1721–2.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mamoudjy et al. Orphanet Journal of Rare Diseases  (2017) 12:33 Page 7 of 7
